Replimune Group (NASDAQ:REPL) Releases Quarterly Earnings Results, Misses Estimates By $0.10 EPS
Replimune Group (NASDAQ:REPL) posted its quarterly earnings data on Thursday. The company reported ($0.46) EPS for the quarter, missing the consensus estimate of ($0.36) by ($0.10), Fidelity Earnings reports.
Shares of NASDAQ REPL traded down $0.14 during trading hours on Friday, hitting $16.85. 67,591 shares of the stock were exchanged, compared to its average volume of 117,261. The company has a quick ratio of 9.85, a current ratio of 9.85 and a debt-to-equity ratio of 0.16. The company has a market cap of $548.31 million, a PE ratio of -16.20 and a beta of 2.99. The firm has a fifty day moving average price of $16.83 and a 200-day moving average price of $14.17. Replimune Group has a 12 month low of $10.00 and a 12 month high of $19.66.
In related news, Director Jason P. Rhodes purchased 1,100,000 shares of the business’s stock in a transaction on Monday, November 18th. The shares were acquired at an average price of $13.61 per share, for a total transaction of $14,971,000.00. The transaction was disclosed in a filing with the SEC, which is available at this link. Also, major shareholder Fund Iv L.P. Omega purchased 220,000 shares of the business’s stock in a transaction on Monday, November 18th. The shares were bought at an average price of $13.61 per share, for a total transaction of $2,994,200.00. The disclosure for this purchase can be found here. Corporate insiders own 63.18% of the company’s stock.
About Replimune Group
Replimune Group, Inc, a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company uses its proprietary Immulytic platform to design and develop product candidates that are intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of herpes simplex virus 1 that is in Phase I/II clinical trials for a range of solid tumors.
Read More: What is a stock split?
Receive News & Ratings for Replimune Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Replimune Group and related companies with MarketBeat.com's FREE daily email newsletter.